Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 475 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Muscle Wasting Clear all
Completed No phase listed Observational

Effects of Frailty, Sarcopenia and Muscle Wasting on Outcomes of Patients in the Surgical Intensive Care Unit

NCT02270502
View directory record Official record
Conditions
Critical Illness, Sarcopenia, Muscle Wasting
Interventions
Ultrasound Philips CX50, Frailty Index Questionnaire, Muscle strength tests
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 22, 2026, 9:30 PM EDT
Not yet recruiting Early Phase 1 Interventional

Sarcopenia in Chronic Kidney Disease (CKD) Patients

NCT07437053
View directory record Official record
Conditions
Chronic Kidney Disease, Sarcopenia
Interventions
Valine, EEA
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
45 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 22, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

NCT01355497
View directory record Official record
Conditions
Muscle Wasting, Non-Small Cell Lung Cancer
Interventions
GTx-024, placebo
Drug
Lead sponsor
GTx
Industry
Eligibility
30 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
30
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Oct 22, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

A Study of CK-2127107 in Patients With Spinal Muscular Atrophy

NCT02644668
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Placebo, Reldesemtiv 150 mg, Reldesemtiv 450 mg
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
12 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
15
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 22, 2026, 9:30 PM EDT
Completed Not applicable Interventional

Vitamin D for Muscle Metabolic Function in Cancer Cachexia

NCT03144128
View directory record Official record
Conditions
Cancer Cachexia, Vitamin D Deficiency
Interventions
Vitamin D, Placebo
Dietary Supplement
Lead sponsor
David Travis Thomas
Other
Eligibility
45 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 22, 2026, 9:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in Chronic Obstructive Pulmonary Disease (COPD): Aim 2

NCT01624792
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Muscle Wasting
Interventions
Olive oil, Fish oil, Fish oil and placebo
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 22, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement

NCT01369511
View directory record Official record
Conditions
Muscular Atrophy
Interventions
LY2495655, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
16
States / cities
Tucson, Arizona • Laguna Hills, California • Lakewood, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 22, 2026, 9:30 PM EDT
Terminated Not applicable Interventional Results available

Blood Flow Restriction Therapy Following Acute Shoulder Injury Patients

NCT06223373
View directory record Official record
Conditions
Shoulder Injury
Interventions
Blood Flow Restriction, "sham" Blood Flow Restriction
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 22, 2026, 9:30 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Use of Testosterone to Prevent Post-Surgical Muscle Loss - Pilot Study

NCT04456530
View directory record Official record
Conditions
Muscle Atrophy, Surgery, Knee Injuries and Disorders, Complication of Surgical Procedure, Trauma
Interventions
Aveed 750 MG in 3 ML IM Injection, Normal Saline 3 ML IM Injection
Drug · Other
Lead sponsor
The Stone Research Foundation for Sports Medicine and Arthritis
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Oct 22, 2026, 9:30 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals With Androgen Insensitivity

NCT04708431
View directory record Official record
Conditions
Androgen Insensitivity Syndrome, Metabolic Parameters in AIS, CAIS, PAIS and MAIS, Tumor Formation in AIS, CAIS, PAIS and MAIS, Sexual Function AIS, CAIS, PAIS and MAIS
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
8 Years to 99 Years
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2040
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 9:30 PM EDT
Completed No phase listed Observational

Effect of Nusinersen on Adults With Spinal Muscular Atrophy

NCT03878030
View directory record Official record
Conditions
Adult Spinal Muscular Atrophy
Interventions
nusinersen
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 22, 2026, 9:30 PM EDT
Recruiting No phase listed Observational

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

NCT03998202
View directory record Official record
Conditions
Colorectal Cancer, Sarcopenia
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
147
States / cities
Millville, Delaware • Newark, Delaware • Rehoboth Beach, Delaware + 114 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 9:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Efficacy of Protein Supplementation on Attenuating Muscle Atrophy Following Disuse in the Collegiate Population

NCT03454347
View directory record Official record
Conditions
Disuse Atrophy
Interventions
Profile Perform, Lower Limb Suspension
Dietary Supplement · Other
Lead sponsor
South Dakota State University
Other
Eligibility
18 Years to 25 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Brookings, South Dakota
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 22, 2026, 9:30 PM EDT
Recruiting Phase 1 Interventional

A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)

NCT06555419
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Nusinersen, ThecaFlex DRx System
Drug · Device
Lead sponsor
Biogen
Industry
Eligibility
3 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • Palo Alto, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 22, 2026, 9:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Bingocize: A Novel Mobile Application for Older Adult Health

NCT03629912
View directory record Official record
Conditions
Activities of Daily Living, Accidental Fall, Sarcopenia, Arteriosclerosis, Diabetes Mellitus, Type 2, Hypertension, Cognitive Decline, Executive Function, Cognitive Aging
Interventions
Socially-Based Exercise Intervention for Older Adults
Behavioral
Lead sponsor
Western Kentucky University
Other
Eligibility
60 Years to 85 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
4
States / cities
Dixon, Kentucky • Henderson, Tennessee • Johnson City, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 22, 2026, 9:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of 16 Weeks of Hip Adduction and Abduction Resistance Exercise

NCT01228877
View directory record Official record
Conditions
Osteoporosis, Osteopenia, Sarcopenia
Interventions
exercise
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
25 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 22, 2026, 9:30 PM EDT
Completed Not applicable Interventional Results available

The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy.

NCT04675775
View directory record Official record
Conditions
Cirrhosis, Ascites, Liver Diseases, Frailty, Sarcopenia, Hepatic Encephalopathy
Interventions
Medically-tailored meals (MTM), Protein supplements, Nutrition education handout
Other · Dietary Supplement · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 22, 2026, 9:30 PM EDT
Not listed Not applicable Interventional

Effects of a Weight Based Training Program on MS Patients

NCT04002492
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Bodyweight training
Behavioral
Lead sponsor
Holy Name Medical Center, Inc.
Other
Eligibility
40 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Oct 22, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)

NCT03452488
View directory record Official record
Conditions
Sarcopenia, Gait Disorders in Old Age, Muscle Weakness
Interventions
BIO101, Placebo
Drug
Lead sponsor
Biophytis
Industry
Eligibility
65 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
19
States / cities
Banning, California • Garden Grove, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 22, 2026, 9:30 PM EDT
Completed Phase 2 Interventional

Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty

NCT05283486
View directory record Official record
Conditions
Sarcopenia, Frailty, Aging
Interventions
MYMD-1 600MG, MYMD-1 750mg, MYMD-1 900mg, MYMD-1 1050mg, placebo 600mg, placebo 750mg, placebo 900mg, placebo 1050mg
Drug
Lead sponsor
TNF Pharmaceuticals, Inc.
Industry
Eligibility
65 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Clearwater, Florida • Tampa, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 22, 2026, 9:30 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of FDY-5301 in Major Trauma Patients in ICU

NCT04430283
View directory record Official record
Conditions
ICU Acquired Weakness
Interventions
FDY-5301, Placebo
Drug · Other
Lead sponsor
Faraday Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Torrance, California • Gainesville, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 22, 2026, 9:30 PM EDT
Completed Phase 1Phase 2 Interventional

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients

NCT05517603
View directory record Official record
Conditions
Spinal and Bulbar Muscular Atrophy, Kennedy's Disease
Interventions
AJ201, Placebo
Drug
Lead sponsor
AnnJi Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Orange, California • Palo Alto, California • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 22, 2026, 9:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nutritional and Contractile Regulation of Muscle Growth

NCT00891696
View directory record Official record
Conditions
Sarcopenia
Interventions
Rapamycin, Amino acid supplementation, Low-intensity resistance exercise, Sodium nitroprusside, Blood flow restriction cuff
Drug · Other · Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 85 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 22, 2026, 9:30 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

NCT07221669
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Salanersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
0 Days to 42 Days
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Chicago, Illinois • Flower Mound, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 9:30 PM EDT